Becker's Healthcare March 25, 2025
The growing prevalence of ultrahigh-cost drugs under development is prompting health systems nationwide to rethink strategies around access, financial management and workforce preparedness.
These therapies, including cell and gene treatments, present certain financial and logistical hurdles that require special planning and collaboration.
A Dec. 9 forecast published in the American Journal of Health-System Pharmacy, highlighted the urgent need for pharmacies to develop sustainable financial models and strategic plans to address reimbursement complexities and ensure access as some ultrahigh-cost drugs can cost over $1 million per patient.
Currently, the most expensive drug in the U.S. is Lenmeldy, a $4.25 million gene...
Today's Sponsors
Today's Sponsor
